Ladenburg Thalmann announced that Kevin DeGeeter has rejoined the firm as a managing director in its equity research department, effective June 2025.
In this role, Mr. DeGeeter will lead equity research coverage of oncology, infectious disease, and cell therapy companies, with a focus on businesses with market capitalizations ranging from $50 million to $5 billion. Prior to rejoining Ladenburg Thalmann, he was an analyst at Oppenheimer & Co., where he covered small-cap molecular diagnostics and biotech stocks.
Mr. DeGeeter brings more than two decades of experience in both buyside and sell-side research, along with a strong track record in biotechnology and molecular diagnostics. He holds a BA in Economics from Colgate University.
